Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma

Medical Oncology

Volumn 31, Issue 1, 2014, Pages

  Sun, Qi Kai ^a   Zhu, Jian Yu ^a   Wang, Wei ^a   Lv, Yang ^a   Zhou, Hang Cheng ^a   Yu, Ji Hai ^a   Xu, Ge Liang ^a,b   Ma, Jin Liang ^a   Zhong, Wen ^a   Jia, Wei Dong ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery   (China)

Author keywords

Diagnosis; Metastasis; Peroxiredoxin 1; Prognosis; Tumor angiogenesis

Indexed keywords

ALPHA FETOPROTEIN; CD31 ANTIGEN; PEROXIREDOXIN 1; VASCULOTROPIN; PEROXIREDOXIN; PRDX1 PROTEIN, HUMAN;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CAPILLARY DENSITY; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER; LIVER CELL CARCINOMA; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR VOLUME; YOUNG ADULT; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; LIVER NEOPLASMS; METABOLISM; METASTASIS; MICROCIRCULATION; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PEROXIREDOXINS; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84888328045     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0786-2     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-91.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27.
4. Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28:32-40. (Pubitemid 36051004)
5. Kim JH, Lee JM, Lee HN, Kim EK, Ha B, Ahn SM, et al. RNA-binding properties and RNA chaperone activity of human peroxiredoxin 1. Biochem Biophys Res Commun. 2012;425:730-4.
6. Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett. 1999;145:127-32. (Pubitemid 29459080)
7. Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol. 2006;175:1512-6.
8. Kim JH, Bogner PN, Baek SH, Ramnath N, Liang P, Kim HR, et al. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res. 2008;14:2326-33. (Pubitemid 351551064)
9. Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA, Gollnick SO. Peroxiredoxin 1 controls prostate cancer growth through toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res. 2011;71:1637-46.
10. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003;424:561-5. (Pubitemid 36975778)
11. Hoshino I, Matsubara H, Hanari N, Mori M, Nishimori T, Yoneyama Y, et al. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res. 2005;11:7945-52. (Pubitemid 41611642)
12. Song IS, Kim SU, Oh NS, Kim J, Yu DY, Huang SM, et al. Peroxiredoxin I contributes to TRAIL resistance through suppression of redox-sensitive caspase activation in human hepatoma cells. Carcinogenesis. 2009;30:1106-14.
13. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
14. Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, et al. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol. 2004;24:3992-4003. (Pubitemid 38496176)
15. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-33.
16. Qiao B, Wang J, Xie J, Niu Y, Ye S, Wan Q, et al. Detection and identification of peroxiredoxin 3 as a biomarker in hepatocellular carcinoma by a proteomic approach. Int J Mol Med. 2012;29:832-40.
17. Rostila A, Puustinen A, Toljamo T, Vuopala K, Lindström I, Nyman TA, et al. Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure. Lung Cancer. 2012;77:450-9.
18. Du ZX, Yan Y, Zhang HY, Liu BQ, Gao YY, Niu XF, et al. Suppression of MG132-mediated cell death by peroxiredoxin 1 through influence on ASK1 activation in human thyroid cancer cells. Endocr Relat Cancer. 2010;17:553-60.
19. Ha B, Kim EK, Kim JH, Lee HN, Lee KO, Lee SY, et al. Human peroxiredoxin 1 modulates TGF-β1-induced epithelial-mesenchymal transition through its peroxidase activity. Biochem Biophys Res Commun. 2012;421:33-7.
20. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006;12:5369-76. (Pubitemid 44497250)
21. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-8.
22. Chen ZB, Shen SQ, Ding YM, Wang WX, Tao JP, Liang LJ, et al. The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus. Med Oncol. 2009;26:365-71.
23. Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 2006;26:414-23.
24. Riddell JR, Maier P, Sass SN, Moser MT, Foster BA, Gollnick SO. Peroxiredoxin 1 stimulates endothelial cell expression of VEGF via TLR4 dependent activation of HIF-1α. PLoS ONE. 2012;7:e50394.
25. Kim JH, Bogner PN, Ramnath N, Park Y, Yu J, Park YM. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res. 2007;13:3875-82. (Pubitemid 47037594)
26. Yonglitthipagon P, Pairojkul C, Chamgramol Y, Loukas A, Mulvenna J, Bethony J, et al. Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin - binding phosphoprotein 50 in cholangiocarcinoma. Hum Pathol. 2012;43:1719-30.
27. Li J, Yang ZL, Ren X, Zou Q, Yuan Y, Liang L, et al. ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Tumour Biol. 2013;34:359-68.